# HUTCHMED completes Savolitinib trial enrollment

- Link: https://www.directorstalkinterviews.com/hutchmed-completes-savolitinib-trial-enrollment/4121193185
- Published: 2025-04-22T07:24:14+01:00
- Author: Amilia Stone

**HUTCHMED (China) Limited** (Nasdaq/LON:HCM; HKEX:13) has announced that it has
completed enrollment of the registration phase of its Phase II trial of savolitinib
in gastric cancer patients with _MET_ amplification.

This clinical trial is a single-arm, multi-center, open-label, Phase II registration
study to evaluate the efficacy, safety and tolerability of savolitinib in treating
gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma patients with _MET_
amplification. Primary endpoint is objective response rate (ORR) evaluated by the
Independent Review Committee (IRC) (RECIST 1.1). Secondary endpoints include progression
free survival (PFS) and incidence of various adverse events (AE), among others. 
A total of 64 patients have been enrolled in the study. Further details may be found
at clinicaltrials.gov using identifier NCT04923932.

As reported at the American Association for Cancer Research Annual Meeting, interim
results from the study showed a 45% ORR confirmed by IRC and a 50% ORR in patients
with high _MET_ gene copy number. 4‑month duration of response (DOR) rate was 85.7%
with median follow up time of 5.5 months. The most common grade 3 or higher treatment-
related adverse events (TRAE) (≥ 5%) were platelet count decreased, hypersensitivity,
anemia, neutropenia and hepatic function abnormal. Only one patient discontinued
treatment due to grade 4 liver function abnormal (TRAE) and no patient died due 
to TRAE.

The China’s National Medical Products Administration (NMPA) has granted Breakthrough
Therapy Designation to savolitinib for the treatment of locally advanced or metastatic
gastric cancer or GEJ adenocarcinoma patients with _MET_ amplification who have 
failed at least two lines of standard therapies. If positive, HUTCHMED may initiate
plans to apply for marketing authorization of savolitinib for gastric cancer in 
China in late 2025.

Share on:
